Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

NCT02293954 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Colon Cancer
Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Gastrointestinal Cancer
Liver and Intrahepatic Biliary Tract Cancer
Lung Cancer
Metastatic Cancer
Pancreatic Cancer
Rectal Cancer
Thyroid Gland Medullary Carcinoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

PROCEDURE: radionuclide imaging
PROCEDURE: positron emission tomography
OTHER: laboratory biomarker analysis
OTHER: pharmacological study
DRUG: Cu 64 anti-CEA monoclonal antibody M5A IV

Sponsor

City of Hope Medical Center

Collaborators

[object Object]